clusivity in 2008. The main treatment options available in the osteoporosis therapeutics market include alendronate, Reclast, Actonel, Boniva, Evista, Prolia, Forteo (teriparatide), Miacalcin (calcitonin salmon), Prempro (estrogen) and Premarin (conjugated estrogens and medroxyprogesterone acetate) among others.
Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).
The report provides information on the key drivers and challenges of the osteoporosis therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) osteoporosis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as osteoclast activity inhibitors, osteoclast activity promoters, bone anabolic agents, SERMs, SARMs, RANKL inhibitors, dual acting bone agents, PTH release stimulator, cathepsin K inhibitor, bone morphogenetic protein signaler, aminobisphosphonate, DKK1 Protein inhibitor and osteoblast level promotor
- Analysis of the current and future competition in the seven key countries osteoporosis therapeutics market. Key market players covered are Amgen, Merck, Novartis, Pfizer, Osteologix, EffRx, Zydus, Astellas and Radius.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoporosis therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in osteoporosis therapeutics maPage: 1 2 3 4 5 6 7 8 9 10 11 12 Related medicine technology :1
. Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis2
. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets3
. Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial4
. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion5
. Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis6
. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)7
. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis8
. ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination9
. Commonly Prescribed Osteoporosis Drug Associated with Very Low Risk of Serious Jaw Disease10
. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention11
. $1,700,000 Funding of NeoStems Very Small Embryonic-Like Stem Cells Being Developed to Treat Osteoporosis Recommended by the Department of Defense Peer Reviewed Medical Research Program